drugset / Trial / NCT06611150
Concurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyngeal Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to determine the maximum tolerated dose and the recommended phase II dose for nab-paclitaxel when administered concurrently with radiotherapy in nasopharyngeal carcinoma. Researchers will observe the toxicity response of patients receiving nab-paclitaxel at 180 mg/m², 200 mg/m², 230 mg/m², and 260 mg/m².
Timeline
- Start
- 2024-08-02
- Primary completion
- 2025-08-01
- Completion
- 2027-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nab-paclitaxel | Small molecule | 180 mg/m2 | — |
| Subject | Nab-paclitaxel | Small molecule | 200 mg/m2 | — |
| Subject | Nab-paclitaxel | Small molecule | 230 mg/m2 | — |
| Subject | Nab-paclitaxel | Small molecule | 260 mg/m2 | — |